Ann W. St. Claire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ann W. St. Claire has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Amy B LaFrance
HealthPartners Institute, Minneapolis, Minnesota, USA
2 shared publications- Michael V. Maciosek
HealthPartners Institute, Minneapolis, Minnesota
2 shared publications - Raymond G. Boyle
Independent Researcher, Minneapolis, MN
2 shared publications Zack Xu
HealthPartners Institute, Minneapolis, Minnesota, USA
2 shared publicationsBarbara A Schillo
ClearWay Minnesota, Minneapolis, Minnesota, USA
1 shared publicationBarbara A. Schillo
Schroeder Institute, Truth Initiative, Washington, District of Columbia
1 shared publication
Latest Publications
- Open Access
- 9 July 2021
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 56 (11) , 1586-1592
Examining Use and Dual Use of Tobacco Products and Marijuana among Minnesota Adults
An increasing number of states are legalizing the medicinal and/or recreational use of marijuana. Adult perceptions of harm have decreased and marijuana use has increased. This is in contrast to de...
- 9 July 2021
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 56 (11) , 1586-1592
Open AccessExamining Use and Dual Use of Tobacco Products and Marijuana among Minnesota Adults
An increasing number of states are legalizing the medicinal and/or recreational use of marijuana. Adult perceptions of harm have decreased and marijuana use has increased. This is in contrast to de...
- 16 July 2020
- Published by BMJ in Tobacco Control
- Vol. 30 (5) , 530-533
Defining adult e-cigarette prevalence: comparing a categorical definition with days of use
Introduction Electronic cigarette use has grown substantially and the health effects are being closely monitored. Tracking the evolving market place and the profile of adult users is important for tobacco control efforts; however, several different ways of measuring current use have been reported. This paper examines how well a categorical definition aligns with days of use. Methods Data from the 2018 Minnesota Adult Tobacco Survey assessed e-cigarette use based on days of use in the past month and currently using ‘every day, some days, or not at all’. Prevalence of current use and agreement of >1, >5 and >20 days of use with every day or some days were calculated. Results The prevalence of e-cigarette use varied by category of use from 2.4% (≥20 days/30) to 6.0% (≥1 day/30). The highest prevalence was found among young adults reporting any use in the past 30 days (21.9%). Never smokers had low prevalence overall; however, 4.4% reported using in the past 30 days. Using at least 1 day in the past 30 days included a higher proportion of young adults (pConclusions Prevalence and sociodemographics varied by definition of use. Asking ‘every day, some days or not at all’ in population-based studies has the advantage of aligning with cigarette smoking current use definition.
- 16 July 2020
- Published by BMJ in Tobacco Control
- Vol. 30 (5) , 530-533
Defining adult e-cigarette prevalence: comparing a categorical definition with days of use
Introduction Electronic cigarette use has grown substantially and the health effects are being closely monitored. Tracking the evolving market place and the profile of adult users is important for tobacco control efforts; however, several different ways of measuring current use have been reported. This paper examines how well a categorical definition aligns with days of use. Methods Data from the 2018 Minnesota Adult Tobacco Survey assessed e-cigarette use based on days of use in the past month and currently using ‘every day, some days, or not at all’. Prevalence of current use and agreement of >1, >5 and >20 days of use with every day or some days were calculated. Results The prevalence of e-cigarette use varied by category of use from 2.4% (≥20 days/30) to 6.0% (≥1 day/30). The highest prevalence was found among young adults reporting any use in the past 30 days (21.9%). Never smokers had low prevalence overall; however, 4.4% reported using in the past 30 days. Using at least 1 day in the past 30 days included a higher proportion of young adults (pConclusions Prevalence and sociodemographics varied by definition of use. Asking ‘every day, some days or not at all’ in population-based studies has the advantage of aligning with cigarette smoking current use definition.
- 19 March 2020
- Published by BMJ in Tobacco Control
- Vol. 30 (2) , 231-233
Projecting the future impact of past accomplishments in tobacco control
Background: The benefits to adults who quit smoking increase over time as former smokers live longer, healthier lives. Youth who never smoke will benefit for decades. Thus, the long-term population effects of tobacco prevention and control policies may be substantial. Yet they are rarely quantified in evaluations of state tobacco control programmes.Methods: Using a microsimulation model, we predicted the benefits to Minnesotans from 2018 to 2037 of having reduced cigarette smoking prevalence from 1998 to 2017. We first simulated the health and economic harms of tobacco that would have occurred had smoking prevalence stayed at 1997 levels. The harms produced by that scenario were then compared with harms in scenarios with smoking declining at observed rates from 1998 to 2017 and either expected declines from 2018 to 2037 or a greater decline to 5% prevalence in 2037.Results: With expected smoking prevalence decreases from 2018 to 2037, Minnesotans will experience 12 298 fewer cancers, 72 208 fewer hospitalisations for cardiovascular disease and diabetes, 31 913 fewer respiratory disease hospitalisations, 14 063 fewer smoking-attributable deaths, $10.2 billion less in smoking-attributable medical expenditures and $9.4 billion in productivity gains than if prevalence had stayed at 1997 levels. These gains are two to four times greater than for the previous 20 years, and would be about 15% higher if Minnesota achieves a 5% adult prevalence rate by 2037.Conclusions: The tobacco control measures implemented from 1998 to 2017 will produce accelerated benefits during 2018–2037 if modest progress in tobacco prevalence rates is maintained.
- 19 March 2020
- Published by BMJ in Tobacco Control
- Vol. 30 (2) , 231-233
Projecting the future impact of past accomplishments in tobacco control
Background: The benefits to adults who quit smoking increase over time as former smokers live longer, healthier lives. Youth who never smoke will benefit for decades. Thus, the long-term population effects of tobacco prevention and control policies may be substantial. Yet they are rarely quantified in evaluations of state tobacco control programmes.Methods: Using a microsimulation model, we predicted the benefits to Minnesotans from 2018 to 2037 of having reduced cigarette smoking prevalence from 1998 to 2017. We first simulated the health and economic harms of tobacco that would have occurred had smoking prevalence stayed at 1997 levels. The harms produced by that scenario were then compared with harms in scenarios with smoking declining at observed rates from 1998 to 2017 and either expected declines from 2018 to 2037 or a greater decline to 5% prevalence in 2037.Results: With expected smoking prevalence decreases from 2018 to 2037, Minnesotans will experience 12 298 fewer cancers, 72 208 fewer hospitalisations for cardiovascular disease and diabetes, 31 913 fewer respiratory disease hospitalisations, 14 063 fewer smoking-attributable deaths, $10.2 billion less in smoking-attributable medical expenditures and $9.4 billion in productivity gains than if prevalence had stayed at 1997 levels. These gains are two to four times greater than for the previous 20 years, and would be about 15% higher if Minnesota achieves a 5% adult prevalence rate by 2037.Conclusions: The tobacco control measures implemented from 1998 to 2017 will produce accelerated benefits during 2018–2037 if modest progress in tobacco prevalence rates is maintained.
- 1 October 2019
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 57 (4) , e103-e115
The Minnesota SimSmoke Tobacco Control Policy Model of Smokeless Tobacco and Cigarette Use
- 1 October 2019
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 57 (4) , e103-e115
The Minnesota SimSmoke Tobacco Control Policy Model of Smokeless Tobacco and Cigarette Use
- Open Access
- 14 August 2019
- Published by BMJ in Tobacco Control
- Vol. 29 (5) , 564-569
Twenty-year health and economic impact of reducing cigarette use: Minnesota 1998–2017
Background: Adult smoking prevalence in Minnesota fell from 21.8% in 1997 to 15.2% in 2016. This reduction improved heart and lung health, prevented cancers, extended life and reduced healthcare costs, but quantifying these benefits is difficult.Methods: 1.3 million individuals were simulated in a tobacco policy model to estimate the gains to Minnesotans from 1998 to 2017 in health, medical spending reductions and productivity gains due to reduced cigarette smoking. A constant prevalence scenario was created to simulate the tobacco harms that would have occurred had smoking prevalence stayed at 1997 levels. Those harms were compared with tobacco harms from a scenario of actual smoking prevalence in Minnesota from 1998 to 2017.Results: The simulation model predicts that reducing cigarette smoking from 1998 to 2017 has prevented 4560 cancers, 31 691 hospitalisations for cardiovascular disease and diabetes, 12 881 respiratory disease hospitalisations and 4118 smoking-attributable deaths. Minnesotans spent an estimated $2.7 billion less in medical care and gained $2.4 billion in paid and unpaid productivity, inflation adjusted to 2017 US$. In sensitivity analysis, medical care savings ranged from $1.7 to $3.6 billion.Conclusions: Minnesota’s investment in comprehensive tobacco control measures has driven down smoking rates, saved billions in medical care and productivity costs and prevented tobacco related diseases of its residents. The simulation method employed in this study can be adapted to other geographies and time periods to bring to light the invisible gains of tobacco control.- 14 August 2019
- Published by BMJ in Tobacco Control
- Vol. 29 (5) , 564-569
Open AccessTwenty-year health and economic impact of reducing cigarette use: Minnesota 1998–2017
Background: Adult smoking prevalence in Minnesota fell from 21.8% in 1997 to 15.2% in 2016. This reduction improved heart and lung health, prevented cancers, extended life and reduced healthcare costs, but quantifying these benefits is difficult.Methods: 1.3 million individuals were simulated in a tobacco policy model to estimate the gains to Minnesotans from 1998 to 2017 in health, medical spending reductions and productivity gains due to reduced cigarette smoking. A constant prevalence scenario was created to simulate the tobacco harms that would have occurred had smoking prevalence stayed at 1997 levels. Those harms were compared with tobacco harms from a scenario of actual smoking prevalence in Minnesota from 1998 to 2017.Results: The simulation model predicts that reducing cigarette smoking from 1998 to 2017 has prevented 4560 cancers, 31 691 hospitalisations for cardiovascular disease and diabetes, 12 881 respiratory disease hospitalisations and 4118 smoking-attributable deaths. Minnesotans spent an estimated $2.7 billion less in medical care and gained $2.4 billion in paid and unpaid productivity, inflation adjusted to 2017 US$. In sensitivity analysis, medical care savings ranged from $1.7 to $3.6 billion.Conclusions: Minnesota’s investment in comprehensive tobacco control measures has driven down smoking rates, saved billions in medical care and productivity costs and prevented tobacco related diseases of its residents. The simulation method employed in this study can be adapted to other geographies and time periods to bring to light the invisible gains of tobacco control.